Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward.

Stenzel AE, Abrams SI, Moysich KB.

Front Immunol. 2019 Jul 9;10:1608. doi: 10.3389/fimmu.2019.01608. eCollection 2019. Review.

2.

Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs.

Mastio J, Condamine T, Dominguez G, Kossenkov AV, Donthireddy L, Veglia F, Lin C, Wang F, Fu S, Zhou J, Viatour P, Lavilla-Alonso S, Polo AT, Tcyganov EN, Mulligan C Jr, Nam B, Bennett J, Masters G, Guarino M, Kumar A, Nefedova Y, Vonderheide RH, Languino LR, Abrams SI, Gabrilovich DI.

J Exp Med. 2019 Sep 2;216(9):2150-2169. doi: 10.1084/jem.20181952. Epub 2019 Jun 25.

PMID:
31239386
3.

Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma.

Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI.

J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0.

4.

Inhibition of platelet GPVI induces intratumor hemorrhage and increases efficacy of chemotherapy in mice.

Volz J, Mammadova-Bach E, Gil-Pulido J, Nandigama R, Remer K, Sorokin L, Zernecke A, Abrams SI, Ergün S, Henke E, Nieswandt B.

Blood. 2019 Jun 20;133(25):2696-2706. doi: 10.1182/blood.2018877043. Epub 2019 Apr 5.

PMID:
30952674
5.

Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.

Singel KL, Emmons TR, Khan ANH, Mayor PC, Shen S, Wong JT, Morrell K, Eng KH, Mark J, Bankert RB, Matsuzaki J, Koya RC, Blom AM, McLeish KR, Qu J, Ram S, Moysich KB, Abrams SI, Odunsi K, Zsiros E, Segal BH.

JCI Insight. 2019 Mar 7;4(5). pii: 122311. doi: 10.1172/jci.insight.122311. eCollection 2019 Mar 7.

6.

IFN regulatory factor-8 expression in macrophages governs an antimetastatic program.

Twum DY, Colligan SH, Hoffend NC, Katsuta E, Cortes Gomez E, Hensen ML, Seshadri M, Nemeth MJ, Abrams SI.

JCI Insight. 2019 Feb 7;4(3). pii: 124267. doi: 10.1172/jci.insight.124267. [Epub ahead of print]

7.

An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D, Celis E, Abrams SI, Ozato K, Liu K.

J Clin Invest. 2018 Dec 3;128(12):5549-5560. doi: 10.1172/JCI123360. Epub 2018 Nov 5.

8.

Loss of amphiregulin reduces myoepithelial cell coverage of mammary ducts and alters breast tumor growth.

Mao SPH, Park M, Cabrera RM, Christin JR, Karagiannis GS, Oktay MH, Zaiss DMW, Abrams SI, Guo W, Condeelis JS, Kenny PA, Segall JE.

Breast Cancer Res. 2018 Oct 26;20(1):131. doi: 10.1186/s13058-018-1057-0.

9.

Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy.

Orillion A, Damayanti NP, Shen L, Adelaiye-Ogala R, Affronti H, Elbanna M, Chintala S, Ciesielski M, Fontana L, Kao C, Elzey BD, Ratliff TL, Nelson DE, Smiraglia D, Abrams SI, Pili R.

Clin Cancer Res. 2018 Dec 15;24(24):6383-6395. doi: 10.1158/1078-0432.CCR-18-0980. Epub 2018 Sep 6.

PMID:
30190370
10.

Inhibition of Casein Kinase 2 Disrupts Differentiation of Myeloid Cells in Cancer and Enhances the Efficacy of Immunotherapy in Mice.

Hashimoto A, Gao C, Mastio J, Kossenkov A, Abrams SI, Purandare AV, Desilva H, Wee S, Hunt J, Jure-Kunkel M, Gabrilovich DI.

Cancer Res. 2018 Oct 1;78(19):5644-5655. doi: 10.1158/0008-5472.CAN-18-1229. Epub 2018 Aug 23.

PMID:
30139814
11.

Case Study in International Cooperation: Cuba's Molecular Immunology Center and Roswell Park Cancer Institute.

Evans R, Reid M, Segal B, Abrams SI, Lee K.

MEDICC Rev. 2018 Apr;20(2):35-39.

12.

Tumor-derived thymic stromal lymphopoietin enhances lung metastasis through an alveolar macrophage-dependent mechanism.

Burkard-Mandel L, O'Neill R, Colligan S, Seshadri M, Abrams SI.

Oncoimmunology. 2018 Jan 16;7(5):e1419115. doi: 10.1080/2162402X.2017.1419115. eCollection 2018.

13.

Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium.

Hong CC, Sucheston-Campbell LE, Liu S, Hu Q, Yao S, Lunetta KL, Haddad SA, Ruiz-Narváez EA, Bensen JT, Cheng TD, Bandera EV, Rosenberg LA, Haiman CA, Lee K, Evans SS, Abrams SI, Repasky EA, Olshan AF, Palmer JR, Ambrosone CB.

Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):321-330. doi: 10.1158/1055-9965.EPI-17-0434. Epub 2018 Jan 16.

14.

β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.

Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA.

Cancer Res. 2017 Oct 15;77(20):5639-5651. doi: 10.1158/0008-5472.CAN-17-0546. Epub 2017 Aug 17.

15.

A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB.

Clin Cancer Res. 2017 Sep 1;23(17):5055-5065. doi: 10.1158/1078-0432.CCR-16-2946. Epub 2017 Jun 19.

16.

Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry.

Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, Bonilla FA, Buckley RH, Sullivan KE, Ballas ZK, Cunningham-Rundles C, Segal BH.

J Allergy Clin Immunol. 2018 Mar;141(3):1028-1035. doi: 10.1016/j.jaci.2017.05.024. Epub 2017 Jun 9.

17.

Editorial: The rebirth of myeloid-derived suppressor cells: from adversary in cancer to ally in reproductive health.

Abrams SI.

J Leukoc Biol. 2017 May;101(5):1079. doi: 10.1189/jlb.1CE1216-525R. No abstract available.

PMID:
28468987
18.

The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.

Netherby CS, Messmer MN, Burkard-Mandel L, Colligan S, Miller A, Cortes Gomez E, Wang J, Nemeth MJ, Abrams SI.

J Immunol. 2017 May 15;198(10):4129-4139. doi: 10.4049/jimmunol.1601722. Epub 2017 Mar 29.

19.

The Dr. Jekyll and Mr. Hyde complexity of the macrophage response in disease.

Twum DYF, Burkard-Mandel L, Abrams SI.

J Leukoc Biol. 2017 Aug;102(2):307-315. doi: 10.1189/jlb.4MR1116-479R. Epub 2017 Feb 13. Review.

20.

Mechanisms overseeing myeloid-derived suppressor cell production in neoplastic disease.

Netherby CS, Abrams SI.

Cancer Immunol Immunother. 2017 Aug;66(8):989-996. doi: 10.1007/s00262-017-1963-5. Epub 2017 Feb 21. Review.

21.

Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS.

Elife. 2016 Dec 8;5. pii: e17375. doi: 10.7554/eLife.17375.

22.

Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, Abrams SI, Orend G, Gachet C, Mangin PH.

JCI Insight. 2016 Sep 8;1(14):e88245. doi: 10.1172/jci.insight.88245.

23.

No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.

Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph JM, Mayor P, Abrams SI, Segal BH, Wallace PK, Soh KT, Zsiros E, Anton-Culver H, Bandera EV, Beckmann MW, Berchuck A, Bjorge L, Bruegl A, Campbell IG, Campbell SP, Chenevix-Trench G, Cramer DW, Dansonka-Mieszkowska A, Dao F, Diergaarde B, Doerk T, Doherty JA, du Bois A, Eccles D, Engelholm SA, Fasching PA, Gayther SA, Gentry-Maharaj A, Glasspool RM, Goodman MT, Gronwald J, Harter P, Hein A, Heitz F, Hillemmanns P, Høgdall C, Høgdall EV, Huzarski T, Jensen A, Johnatty SE, Jung A, Karlan BY, Klapdor R, Kluz T, Konopka B, Kjær SK, Kupryjanczyk J, Lambrechts D, Lester J, Lubiński J, Levine DA, Lundvall L, McGuire V, McNeish IA, Menon U, Modugno F, Ness RB, Orsulic S, Paul J, Pearce CL, Pejovic T, Pharoah P, Ramus SJ, Rothstein J, Rossing MA, Rübner M, Schildkraut JM, Schmalfeldt B, Schwaab I, Siddiqui N, Sieh W, Sobiczewski P, Song H, Terry KL, Van Nieuwenhuysen E, Vanderstichele A, Vergote I, Walsh CS, Webb PM, Wentzensen N, Whittemore AS, Wu AH, Ziogas A, Odunsi K, Chang-Claude J, Goode EL, Moysich KB; Australian Ovarian Cancer Study.

Cancer Epidemiol Biomarkers Prev. 2017 Mar;26(3):420-424. doi: 10.1158/1055-9965.EPI-16-0631. Epub 2016 Sep 27.

24.

Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence.

Minderman H, Maguire O, O'Loughlin KL, Muhitch J, Wallace PK, Abrams SI.

Methods. 2017 Jan 1;112:84-90. doi: 10.1016/j.ymeth.2016.08.011. Epub 2016 Aug 28.

25.

Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.

Abrams SI, Netherby CS, Twum DY, Messmer MN.

J Interferon Cytokine Res. 2016 Jul;36(7):442-53. doi: 10.1089/jir.2015.0174. Review.

26.

Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5.

Eng JW, Mace TA, Sharma R, Twum DYF, Peng P, Gibbs JF, Pitoniak R, Reed CB, Abrams SI, Repasky EA, Hylander BL.

J Immunother Cancer. 2016 Jun 21;4:33. doi: 10.1186/s40425-016-0136-y. eCollection 2016.

27.

Generation of a C57BL/6 MYC-Driven Mouse Model and Cell Line of Prostate Cancer.

Ellis L, Ku S, Li Q, Azabdaftari G, Seliski J, Olson B, Netherby CS, Tang DG, Abrams SI, Goodrich DW, Pili R.

Prostate. 2016 Sep;76(13):1192-202. doi: 10.1002/pros.23206. Epub 2016 May 26.

28.

Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.

Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO, Abrams SI, Gudkov AV.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E874-83. doi: 10.1073/pnas.1521359113. Epub 2016 Feb 1.

29.

MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction.

Banik D, Netherby CS, Bogner PN, Abrams SI.

Oncotarget. 2015 Jun 20;6(17):15164-79.

30.

Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.

Khan AN, Kolomeyevskaya N, Singel KL, Grimm MJ, Moysich KB, Daudi S, Grzankowski KS, Lele S, Ylagan L, Webster GA, Abrams SI, Odunsi K, Segal BH.

Oncotarget. 2015 May 10;6(13):11310-26.

31.

IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation.

Paschall AV, Zhang R, Qi CF, Bardhan K, Peng L, Lu G, Yang J, Merad M, McGaha T, Zhou G, Mellor A, Abrams SI, Morse HC 3rd, Ozato K, Xiong H, Liu K.

J Immunol. 2015 Mar 1;194(5):2369-79. doi: 10.4049/jimmunol.1402412. Epub 2015 Feb 2.

32.

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.

Messmer MN, Netherby CS, Banik D, Abrams SI.

Cancer Immunol Immunother. 2015 Jan;64(1):1-13. doi: 10.1007/s00262-014-1639-3. Epub 2014 Nov 29. Review.

33.

Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models.

Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, Pili R.

Cancer Immunol Res. 2015 Feb;3(2):136-48. doi: 10.1158/2326-6066.CIR-14-0036. Epub 2014 Nov 4.

34.

Mild cold-stress depresses immune responses: Implications for cancer models involving laboratory mice.

Messmer MN, Kokolus KM, Eng JW, Abrams SI, Repasky EA.

Bioessays. 2014 Sep;36(9):884-91. doi: 10.1002/bies.201400066. Epub 2014 Jul 25. Review.

35.

The curative outcome of radioimmunotherapy in a mouse breast cancer model relies on mTOR signaling.

Verbrugge I, Gasparini A, Haynes NM, Hagekyriakou J, Galli M, Stewart TJ, Abrams SI, Yagita H, Verheij M, Johnstone RW, Borst J, Neefjes J.

Radiat Res. 2014 Aug;182(2):219-29. doi: 10.1667/RR13511.1. Epub 2014 Jun 24. Erratum in: Radiat Res. 2014 Oct;182(4):e45.

PMID:
24960417
36.

Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.

Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI.

J Biol Chem. 2014 May 30;289(22):15642-52. doi: 10.1074/jbc.M113.544320. Epub 2014 Apr 21.

37.

Tumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundance.

Farren MR, Carlson LM, Netherby CS, Lindner I, Li PK, Gabrilovich DI, Abrams SI, Lee KP.

Sci Signal. 2014 Feb 18;7(313):ra16. doi: 10.1126/scisignal.2004656.

38.

Baseline tumor growth and immune control in laboratory mice are significantly influenced by subthermoneutral housing temperature.

Kokolus KM, Capitano ML, Lee CT, Eng JW, Waight JD, Hylander BL, Sexton S, Hong CC, Gordon CJ, Abrams SI, Repasky EA.

Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20176-81. doi: 10.1073/pnas.1304291110. Epub 2013 Nov 18.

39.

Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis.

Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI.

J Clin Invest. 2013 Oct;123(10):4464-78. doi: 10.1172/JCI68189. Epub 2013 Sep 16.

40.

Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice.

Godoy HE, Khan AN, Vethanayagam RR, Grimm MJ, Singel KL, Kolomeyevskaya N, Sexton KJ, Parameswaran A, Abrams SI, Odunsi K, Segal BH.

PLoS One. 2013 Jul 26;8(7):e69631. doi: 10.1371/journal.pone.0069631. Print 2013.

41.

Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer.

Hu X, Bardhan K, Paschall AV, Yang D, Waller JL, Park MA, Nayak-Kapoor A, Samuel TA, Abrams SI, Liu K.

J Biol Chem. 2013 Jun 28;288(26):19103-15. doi: 10.1074/jbc.M112.434530. Epub 2013 May 15.

42.

Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases.

Gil M, Seshadri M, Komorowski MP, Abrams SI, Kozbor D.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):E1291-300. doi: 10.1073/pnas.1220580110. Epub 2013 Mar 18.

43.

Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity.

Banik D, Khan AN, Walseng E, Segal BH, Abrams SI.

PLoS One. 2012;7(9):e45422. doi: 10.1371/journal.pone.0045422. Epub 2012 Sep 19.

44.

Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression.

Abrams SI, Waight JD.

Oncoimmunology. 2012 Jul 1;1(4):550-551.

45.

Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism.

Waight JD, Hu Q, Miller A, Liu S, Abrams SI.

PLoS One. 2011;6(11):e27690. doi: 10.1371/journal.pone.0027690. Epub 2011 Nov 16.

46.

IFN-γ upregulates survivin and Ifi202 expression to induce survival and proliferation of tumor-specific T cells.

Zimmerman M, Yang D, Hu X, Liu F, Singh N, Browning D, Ganapathy V, Chandler P, Choubey D, Abrams SI, Liu K.

PLoS One. 2010 Nov 22;5(11):e14076. doi: 10.1371/journal.pone.0014076.

47.

Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells.

Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, Abrams SI.

J Cell Mol Med. 2009 Sep;13(9B):3939-50. doi: 10.1111/j.1582-4934.2009.00685.x.

48.

A multi-functional role of interferon regulatory factor-8 in solid tumor and myeloid cell biology.

Abrams SI.

Immunol Res. 2010 Mar;46(1-3):59-71. doi: 10.1007/s12026-009-8125-6. Review.

PMID:
19756408
49.

Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells.

Stewart TJ, Liewehr DJ, Steinberg SM, Greeneltch KM, Abrams SI.

J Immunol. 2009 Jul 1;183(1):117-28. doi: 10.4049/jimmunol.0804132. Erratum in: J Immunol. 2009 Aug 15;183(4):2884.

50.

How tumours escape mass destruction.

Stewart TJ, Abrams SI.

Oncogene. 2008 Oct 6;27(45):5894-903. doi: 10.1038/onc.2008.268. Review.

PMID:
18836470

Supplemental Content

Loading ...
Support Center